NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 11:00 a.m. EST. The conference will be held at the Lotte New York Palace.
A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the company’s website for two weeks following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts
Investors:
Lora Pike
Ovid Therapeutics Inc.
lpike@ovidrx.com
Jill Steier
Burns McClellan, Inc.
jsteier@burnsmc.com
(212) 213-0006
Media:
Jerica Pitts
W2O Group
jpitts@w2ogroup.com
(312) 858-3469